Literature DB >> 3338990

Kinetics of activation of the respiratory burst oxidase in a fully soluble system from human neutrophils.

B M Babior1, R Kuver, J T Curnutte.   

Abstract

In a fully soluble system from resting human neutrophils, activation of the respiratory burst oxidase under defined conditions was found to follow first-order kinetics. The manner in which this first-order activation process varied with the concentrations of the individual components in the activating system suggested the following. 1) The respiratory burst oxidase occurs in two forms that can be distinguished by their Km values for NADPH. The low-affinity form contains one component (M) from the membrane and two components (S and C alpha) from the cytosol, while the high-affinity form contains an extra cytosolic component (C beta). 2) The active forms of the oxidase are generated in the following reactions: (formula; see text) where S is a stabilizing component and where M.S is an activated form of M.S that is capable of binding C alpha and C beta to produce the active oxidase species M.S.C alpha (the low-affinity form) and M.S.C alpha C beta (the high-affinity form). 3) SDS activates the oxidase by mediating the conversion of M.S to M.S.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3338990

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Deactivation of neutrophil NADPH oxidase by actin-depolymerizing agents in a cell-free system.

Authors:  M Tamura; M Kanno; Y Endo
Journal:  Biochem J       Date:  2000-07-01       Impact factor: 3.857

2.  Absolute requirement for GTP in activation of human neutrophil NADPH oxidase in a cell-free system: role of ATP in regenerating GTP.

Authors:  P Peveri; P G Heyworth; J T Curnutte
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

Review 3.  The electron transport chain of the microbicidal oxidase of phagocytic cells and its involvement in the molecular pathology of chronic granulomatous disease.

Authors:  A W Segal
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

Review 4.  Protein phosphorylation associated with the stimulation of neutrophils. Modulation of superoxide production by protein kinase C and calcium.

Authors:  P G Heyworth; J A Badwey
Journal:  J Bioenerg Biomembr       Date:  1990-02       Impact factor: 2.945

5.  Spontaneous activation of NADPH oxidase in a cell-free system: unexpected multiple effects of magnesium ion concentrations.

Authors:  A R Cross; R W Erickson; B A Ellis; J T Curnutte
Journal:  Biochem J       Date:  1999-02-15       Impact factor: 3.857

6.  Cytosolic components of the respiratory burst oxidase: resolution of four components, two of which are missing in complementing types of chronic granulomatous disease.

Authors:  J T Curnutte; P J Scott; L A Mayo
Journal:  Proc Natl Acad Sci U S A       Date:  1989-02       Impact factor: 11.205

7.  The cytosolic subunit p67phox contains an NADPH-binding site that participates in catalysis by the leukocyte NADPH oxidase.

Authors:  R M Smith; J A Connor; L M Chen; B M Babior
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

8.  Cloning of the cDNA and functional expression of the 47-kilodalton cytosolic component of human neutrophil respiratory burst oxidase.

Authors:  B D Volpp; W M Nauseef; J E Donelson; D R Moser; R A Clark
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

Review 9.  Mechanisms for the activation/electron transfer of neutrophil NADPH-oxidase complex and molecular pathology of chronic granulomatous disease.

Authors:  S Umeki
Journal:  Ann Hematol       Date:  1994-06       Impact factor: 3.673

10.  Point mutation in the cytoplasmic domain of the neutrophil p22-phox cytochrome b subunit is associated with a nonfunctional NADPH oxidase and chronic granulomatous disease.

Authors:  M C Dinauer; E A Pierce; R W Erickson; T J Muhlebach; H Messner; S H Orkin; R A Seger; J T Curnutte
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.